Terumo Blood and Cell Technologies (BCT) has launched the Quantum Flex Cell Expansion System, a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector.
Responding to the industry’s need for earlier automation to potentially limit additional and time-consuming steps such as bridging studies and technology transfers, Terumo BCT says that Quantum Flex allows developers to complete their early process development on the same platform they will use for manufacturing, creating a cell culture environment where cells thrive. Early process development may lead to reduced cost and risk of unanticipated process deviations in later phases of clinical trials.
Delara Motlagh, General Manager, Cell Therapy Technologies, said: “We developed Quantum Flex to provide a scalable, GMP-compliant platform that streamlines cell manufacturing and data management. We strive to deliver high-quality cells with fast cycle time to achieve timely delivery to market, and ultimately to patients.”
Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, commented: “The Quantum Flex platform represents another advancement which will help streamline processes and accelerate the manufacturing process, making it easier for developers to bring therapies to market.”
